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1. Introduction   
Despite a plateau in the incidence of acute hepatitis C infection since 2003 (Daniels, 2009), 
chronic hepatitis C virus (HCV) infection continues to pose a significant public health 
problem with a large cost burden to society. HCV is the most common blood-borne infection 
in the US with an estimated 3.2 million chronically infected people nationwide (Daniels, 
2009). HCV is the leading cause of chronic liver disease and a major cause of hepatocellular 
carcinoma in the US with an estimated 8,000 to 13,000 deaths annually (Daniels, 2009; Wise 
et al., 2008; Armstrong et al., 2006).   
Injection drug use continues to be the main risk factor leading to HCV infection.  The peak 
prevalence occurs among adults aged 40 to 49 years with individuals of lower socio-
economic status bearing a disproportionate burden compared with other groups (Daniels, 
2009; Armstrong et al., 2006). The majority of liver transplants in this country occur in 
patients with cirrhosis due to HCV (Verna & Brown, 2006; Freeman et al., 2008). It is 
estimated that the associated total direct and indirect cost of HCV associated cirrhosis and 
hepatocellular carcinoma is greater than $5 billion each year (Leigh et al., 2001). 
In California alone, an estimated 600,000 persons have been exposed to HCV and about 
450,000 Californians are living with chronic HCV.  Racial disparities in infection rates exist 
with African Americans having the highest observed rate of HCV infection among all racial 
and ethnic groups.  The prevalence of HCV infection among African Americans living in 
California is estimated at 3.2%, among Latinos, 2.1% and among Caucasians, 1.5% (CDC, 1998). 
2. Closing the gap of access to specialty care 
Prior studies have shown that HCV patients without access to a specialist are less likely to 
be treated (Rocca et al., 2004).  This is significant from a clinical and public health standpoint 
because almost half of patients treated with the current standard of care (6-18 months of 
therapy with pegylated interferons and ribavirin) achieve long term cure with a resultant 
improvement of liver-related mortality rate that approximates the one experienced in the 
general population (Simin et al., 2007; Veldt et al., 2007; Kasahara et al., 2004). 
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Rural communities are particularly affected by the lack of access to specialty care (Yawn et 
al., 2002; Rossaro et al., 2008). Telemedicine consultation offers the potential to increase 
access to specialists in remote and underserved areas.  Increasingly, primary care providers 
(PCPs) in remote areas are being called upon to diagnose and treat patients with HCV.  
Unfortunately, many PCPs are unprepared to evaluate and manage the complexity of 
patients with chronic HCV and practice patterns are highly variable. Few rural practitioners 
have experience with the complex mental health and substance abuse issues that are 
common among patients with hepatitis C infection (Arora et al., 2010). In addition, they may 
perceive greater challenges when managing treatment side effects of pegylated interferons 
and ribavirin (depression, thrombocytopenia, neutropenia, anemia, GI side effects and skin 
rash). Optimal management of HCV infection requires consultation with highly trained 
specialists or academic institutions with dedicated hepatologists. 
Furthermore, it can be difficult for patients with HCV infection living in remote or 
underserved areas to access specialists.  Often patients are required to travel long distances 
to academic centers that offer specialty care, experience long wait times to see specialists at 
these centers, and may not be able to schedule follow up visits in a timely manner due to the 
high volume of patient care at these centers. While undergoing treatment for HCV infection, 
close monitoring and follow up with a specialist and/or close communication between a 
PCP and specialist is essential due to the potentially life threatening side effects of interferon 
and ribavirin.  These factors may impede patients in remote areas from initiating treatment 
for HCV. Table 1 lists the different barriers to care of HCV in rural areas. 
 
Barriers to the Management of HCV in Rural Areas 
• Access to specialists • Lack of transportation 
• Distance to clinic • Limited education of providers 
• Low socioeconomic status  
Table 1. A list of barriers to HCV management that patients in rural areas experience 
Telemedicine can close the gap of access to specialty care and provide clinical decision 
making support to PCPs with regard to best practice treatment strategies for managing HCV 
patients.   In the last ten years, we have provided consultations to patients with HCV via 
telemedicine at about 50 different locations throughout California. Our telemedicine sites 
have included primary clinics in rural areas with a high prevalence of HCV and low 
socioeconomic status as well as correctional facilities.  
3. Use of telemedicine consultation for the management of HCV patients 
Telemedicine is the use of high speed, wide band width transmission of digitized signals in 
conjunction with computers to provide an audio-visual interaction in real time between a 
patient and physician who are physically separated. Telemedicine is an effective tool to 
improve access for patients with HCV in underserved areas. In addition, the presence of the 
PCP in the room with the patient provides educational opportunities for the provider and 
the patient and improves the overall quality of patient care.  
Telemedicine offers a unique opportunity for real time interactions among a triad of 
individuals (Figure 1): the patient, in need of specialty care, the PCP who actively 
participates during the consultation, and the specialist, who provides consultation services 
and education in management to both patient and PCP simultaneously. 
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Fig. 1. Telemedicine Triad: patient, PCP, and specialist with multidirectional interactions in 
real time, providing care and education. 
In a recent retrospective review of our data (Rossaro et al., 2008), we found a surprisingly 
high severity of disease in a difficult to treat population in a rural area in California (Figure 
2 and Table 2). From 2000-2007, we provided consultations for 103 patients with hepatitis C 
living in small California rural communities with high rates of poverty and a high incidence 
of HCV. Of these patients, approximately half (37% Stage 4 + 12% Stage 3 = 49%) had 
advanced fibrosis, and 64% had never undergone therapy with interferon and ribavirin. 
Twenty-three percent of the patients were candidates for therapy. The most common 















Fig. 2. Stage of Fibrosis of patients evaluated by Telemedicine according to the Knodell score 
(Rossaro et al., 2008) 
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Weight (mean) 88.46 kg 
Age (mean) 49 yrs 
Patient Insurance  
       No insurance 6% 
       County 25% 
       Medi-Cal 61% 
       Medicare 6% 
       Private 2% 
 Viral genotype  
               1 71% 
               2 11% 
               3 15% 
               4 2% 
               6 1% 
HCV Viral load > 450,000 IU 37% 
Advanced liver fibrosis 49% 
Model for End Stage Liver Disease 
(MELD) > 12 
19% 
Treatment naïve 64% 
Treatment recommended 23% 
Table 2. Characteristics of Patients evaluated by Telemedicine (Rossaro et al., 2008) 
during treatment due to advanced cirrhosis.  Fifteen patients were evaluated for liver 
transplant. Two patients were listed for transplantation but neither survived long enough to 
receive a liver. 
Our data suggest that a large number of patients with hepatitis C and advanced liver disease 
are living in rural communities, some of whom may need treatment or liver transplant. 
Telemedicine is an effective tool for identifying and treating patients with hepatitis C who live 
in rural communities who may otherwise go untreated or not listed for liver transplantation. 
4. Improving practitioner hepatitis C knowledge by video conferencing 
Telemedicine can also be utilized to provide education to practitioners regarding HCV.  In a 
recent study, we compared the impact of multipoint videoconferencing versus standard 
lecturing on level of knowledge attainment in different groups of PCPs including physicians, 
nurse practitioners, physician assistants, and registered nurses (Rossaro et al., 2007). 
The hypothesis was that the educational impact of teaching through telemedicine is 
comparable to the traditional didactic method. The aim was to provide participants with 
clinically relevant information and knowledge about the natural history, diagnosis, and 
management of HCV. Improved knowledge was scored from a 10-item questionnaire 
administered before and after the educational intervention. For all practitioners combined, 
the videoconferencing group scored significantly lower on the pretest than the standard 
lecturing group (Table 3).  
All three types of learners improved their knowledge scores following intervention in both 
methods. However the videoconferencing group scored significantly higher on the posttest  
 
www.intechopen.com
The Use of Telemedicine for the Management of Hepatitis C & the California Telehealth Network   
 
249 
  All Providers (MDs, NPs/PAs, RNs)  
  Videoconferencing Standard Lecture p value ** 
  n = 62 n = 113  
Pretest Score * 4.3 4.9 <0.05 
Posttest Score * 8.7 7.9 <0.001 
Score Improvement 4.4 3.0 <0.001 
Legend: MDs, Medical Doctors; NPs, Nurse Practitioners; PAs, Physician Assistants; RNs, Registered 
Nurses.  * Pre and Post-test scores range from 0-10 items correct. ** T-test analysis 
Table 3. Knowledge Scores: Videoconferencing Method vs. Standard Lecture 
and had a significantly greater score improvement. Nurses showed the greatest 
improvements, correctly answering an average of four to five more questions following the 
video conferencing educational intervention. The results of this study indicate that video 
conferencing is equivalent, if not better, than standard continuing medical education. Video 
conferencing can potentially improve clinician education regarding the history, diagnosis, 
and management of HCV, thereby making a substantial impact on the clinical course of 
patients with this condition. In addition, video conferencing has the potential to eliminate 
the financial and geographic barriers to professional education for rural practitioners. 
5. Hepatitis C in the correctional system 
HCV infection is rampant within the correctional system. A study of about 4500 inmates 
entering the Californian correctional system found that 39% of males and 53% of females were 
chronically infected. This is becoming a serious concern to public health officials, health care 
providers and policy makers. Infected inmates may continue to engage in high risk behaviors 
and infect others while in custody, they may transmit the disease to people in the community 
to which they are released and the cost of providing care to HCV infected inmates with 
chronic liver disease or hepatocellular carcinoma is rising (Ruiz et al., 1999). Subsequent 
studies have reported the prevalence of HCV to be 34% and independently correlated with 
age, history of intravenous drug use, cumulative time of incarceration, male biological sex > 
female, and history of sex with a male intravenous drug user. (Fox et al., 2005) 
HCV has also been implicated in the high prevalence of end stage liver disease in state 
prisons. A study from Texas with more than 370,000 prisoners during a period of 3.5 years 
found the prevalence of end stage liver disease to be as high as 131 per 100,000 prisoners 
with 57 per 100,000 dying during the study period due to complications of end stage liver 
disease. The estimate of mortality for end stage liver disease in the Texas prison population 
was approximately 3 times higher than that of the general population. Risk of high mortality 
were found in the following groups: Hispanics, greater than 50 yrs of age, HIV 
monoinfected, HCV monoinfected, HCV-HIV coinfected (Baillargeon et al., 2007). 
It has been advocated that inmate education and counseling are important in preventing 
HCV infection as well as HIV and hepatitis B infection. Counseling should be culturally 
appropriate and consistent with the learning skill of the inmate. Prevention strategies 
should be designed to encourage voluntary behavior change and effective risk reduction. 
Finally it has been advocated that an assessment of the risk factor profile of all inmates 
entering the correctional system should be conducted (Ruiz et al. 1999) 
The enormous cost of organ transplantation and management of end stage liver disease are 
serious challenges to the health care budgets of most prison systems. Consequently, it is 
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crucial that correctional health care programs expand HCV treatment and infection 
prevention strategies. (Baillargeon et al., 2007) It is well known that treatment of HCV early 
enough, before end stage liver disease and liver cancer occur, is highly cost effective. While 
HCV therapy appears expensive, many cost effectiveness analysis suggest that treatment 
with Pegylated interferon and ribavirin provides value comparable to many well accepted 
medical interventions (Bhavesh & Wong, 2006).  
A study from the Medical College of Virginia, utilizing telemedicine consultation services, 
showed that HCV therapy can be effectively managed in correctional facilities with response 
rates similar to, if not better than, the non-inmate population (Sterling et al. 2004). This study 
included a retrospective analysis of 59 consecutive inmates who received HCV therapy under 
direct observation with standard interferon (non pegylated, 3 MIU TIW and ribavirin 1000-
1200 mg per day). As expected, sustained virological response (cure) was higher in Caucasians 
(41%) compared with African Americans (28%), although the differences were not statistically 
significant. Even more so, when the analysis was concentrated on HCV genotype 1 alone, 
Caucasians and African Americans performed similarly (33% vs. 29%). The above results are 
remarkable given the fact that non-pegylated based therapy was utilized and partly related to 
the high adherence allowed by direct observation of therapy. 
Since year 2000, at the UC Davis Center for Health Technology, we have provided hundreds 
of telemedicine consultations and videoconferencing educational events with several 
correctional facilities throughout California. We found inmates to be highly motivated to 
initiate treatment and their compliance while on treatment has been excellent. The drop out 
rate while on treatment appears to be similar to that of the non-inmate population (about 
10%) (Unpublished observations). One key factor for successful therapy is continuity of care 
once therapy is initiated. It is desirable that the inmate not be transferred to another facility 
during treatment (6-18months). 
6. Next steps: The California telehealth network 
The California Telehealth Network (CTN) (California Telehealth Network Website, 2010) 
was established in 2007 with a $22.1 million grant from the Federal Communications 
Commission’s Rural Health Care Pilot Program (RHCPP) and matching funds of $3.6 
million from the California Emerging Technology Fund. CTN is a statewide dedicated 
health care broadband network, developed to ensure that California communities, especially 
rural communities, have access to a wide range of telemedicine and eHealth activities.  CTN 
will provide the connectivity necessary to access high quality, collaborative health services, 
continuing education, research and peer networking activities. The connectivity provided by 
the CTN will create new telecommunications infrastructure, eventually allowing 
California’s rural communities to access a broad range of technology-enhanced services to 
improve the quality of health care services in California.  
Collectively, the Federal Communications Commission award and other new resources will 
help California develop an effective, sustainable and forward-looking telehealth network, 
focusing first on rural communities and subsequently expanding to serve increasing numbers 
of California health providers in both rural and urban areas. Over the course of the project, the 
new network will connect more than 860 rural sites with each other, and with a network of 
specialty providers at academic medical centers and other nonprofit and for-profit health 
providers statewide. Strong emphasis will be placed on infrastructure development, 
telecommunications quality and technical support. The University of California (UC), with the 
UC Davis Health System serves as the lead technical and operational entity for the CTN. 
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The California Telehealth Network is intended to improve access within rural and 
underserved areas to high quality, collaborative health services and to make new 
networking capability available for more California health providers. The CTN will link 
California providers to a nationwide broadband network dedicated to health care.   
7. Current research 
New models for delivery of telemedicine delivery have been developed and offer promising 
delivery of specialist services to remote and underserved areas.  One model, The Extension 
for Community Healthcare Outcomes (ECHO) Model was developed by the University of 
New Mexico Health Sciences Center to deliver complex specialty medical care to 
underserved populations (Arora et al., 2007; Arora et al., 2010).  The ECHO model was first 
developed for the management of HCV.  ECHO provides health care delivery and clinical 
education to rural primary care practitioners via video conferencing (Arora et al. 2007). The 
ECHO model uses “telehealth technology, best practice protocols, and case-based learning” 
to train and support primary care providers in the development of their knowledge and self-
efficacy for managing chronic diseases (Arora et al., 2010). Initial survey data of the project 
have demonstrated a significant improvement in provider knowledge, self-efficacy, and 
professional satisfaction through participation in ECHO HCV clinics (Arora et al., 2010).  
However, no patient outcome data are yet available for this project. 
In 2007, we completed a retrospective chart review of 103 telemedicine patients with HCV 
from Peach Tree Clinic in Marysville, California to characterize the patient population seen 
in rural clinics.  The study found that there is a need for more consultation and education of 
primary care providers for patients living with HCV in rural communities, and telemedicine 
appears to be an effective modality for increasing access to liver specialists and education 
(Rossaro et al., 2008).   
Telemedicine consultation offers the potential to increase access to specialists in remote and 
underserved areas and has been successfully utilized in the field of trauma with non-inferior 
outcomes for injured patients treated at rural centers (Duchesne et al., 2008).  To our 
knowledge, however, no studies have examined the utility, safety or efficacy of telemedicine 
for the management of chronic diseases in terms of patient outcomes.   
8. Future research 
8.1 Next steps 
Our next research study will attempt to fill this telemedicine HCV patient outcomes 
research gap.  We will expand our previous observational study and compare actual patient 
outcomes with HCV patients treated via telemedicine consultation at Peach Tree Clinic and 
other telemedicine sites as compared to standard hepatology office practice.  
8.2 Study methods 
We will perform a retrospective analysis, in two phases, using standard chart review of 
HCV patients seen at all available telemedicine sites and the UC Davis Gastroenterology 
(UCD GI) Clinic between the years 2008 and 2010. Our initial retrospective cohort study will 
be a descriptive comparison of telemedicine patients vs. traditional visit patients without 
matching to characterize group differences in these patient populations.  We will attempt to 
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identify general group differences by comparing the following variables between groups:  
mean age at initiation of therapy, gender distribution, ethnicity distribution, hepatitis C 
genotype, stage of fibrosis, viral load at baseline, 4, and 12 weeks after the start of therapy to 
assess for rapid and early virological response, rates of therapy completion and rates/types 
of side effects experienced by patients. Our goal number of cases for each comparison group 
is approximately 50, for a total of 100 patients for this pilot study.   
As a second phase of investigation, we will conduct a case-control study matching 
telemedicine cases with traditional visit controls by age, gender, ethnicity, Hepatitis C 
genotype and stage of fibrosis in order to compare outcomes of early virological response at 
12 weeks and side effect profiles of patients treated with interferon and ribavirin.  Our final 
study will include an anticipated total of 100 controls and 100 telemedicine cases in order to 
achieve a power analysis of 80%. 
Inclusion criteria for study subjects will include: a) age 18-75 years; b) hepatitis C positive by 
PCR; c) treatment naïve; and d) referred for HCV treatment by primary care provider.  
Exclusion criteria will include a) patients active substance use; b) psychiatric diagnosis of 
uncontrolled clinical depression; c) co-infection with HBV or d) co-infection with HIV. 
Once all cases are identified and inclusion criteria are met, we will match each case with at 
least one control patient from the UCDMC based on the following variables: a) age, <50 
years or >=50 years; b) gender; c) ethnicity/race ; d) hepatitis C genotype, type 1 vs. non-1; 
and e) stage of fibrosis (0-2 vs. 3-4).  
Once all cases and controls are matched on the above variables, we will collect outcome data 
on the following variables: a) rapid virologic response at 4 weeks (yes or no); b) viral load at 
4 weeks; c) early virologic response at 12 weeks (yes or no); d) viral load at 12 weeks; e) 
completion of therapy (yes, no or in progress); f) termination of treatment due to side effects 
(yes or no); and g) side effects experienced. 
We will collect data on each patient at 4 and 12 weeks that will allow us to determine 
treatment response and track side effects which include anemia, thrombocytopenia, 
neutropenia, weight loss, rash, fatigue, GI upset and depression.  This data will be collected, 
coded using a standard coding system and entered into a standard database system. This 
patient database will be encrypted with a password as it is developed and accessible only to 
approved research project members for data entry.  Once all data has been collected, this 
data set will be converted into a non-identifiable database and the original encrypted 
database will be kept on a CD ROM in a locked file cabinet inside a locked office.  
8.3 Statistical considerations 
We will consider whether a patient has an early virological response (70% predictive of 
sustained virological response 24 weeks after completion of a 48 week course of treatment) 
after completing therapy for 12 weeks, measured via PCR as the primary endpoint 
(outcome), which is a binary outcome (response) variable.  Let π1 and π2 be the early 
virological response rates in the traditional office visit group and the telemedicine group, 
respectively. We want to test the null hypothesis of no difference in the early virological 
response rate between the two groups (cases and controls), i.e., π1 = π2 (OR = 1), versus the 
alternative hypothesis that there is a difference in the early virological response rate 
between the two groups, i.e., π1 ≠ π2 (OR≠ 1).  Then, a total of 100 patients (50 patients in 
each group) can provide the power of 12.3% to detect the difference of 10% (π1 = 60%, π2 = 
50%) (0.5 in terms of OR) in the early virological response rate between the two groups by 
using two-sided Fisher’s exact test at significance level of 5%.  However, a total of 200 
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patients (100 patients in each group) can provide the power of 80% to detect the difference 
of 11.6% (π1 = 60%, π2 = 48.4%) (0.568 in terms of OR)] in the early virological response rate 
between the two groups by using two-sided Fisher’s exact test at significance level of 5%.   
8.4 Statistical analysis plan 
Cohort comparison group demographics and clinical features will be analyzed qualitatively 
and quantitatively. A Fisher’s exact test will be used to compare each of the dichotomous (or 
polytomous) outcome variables of interest between the two groups. As secondary analyses, 
logistic regression will be used to control for possible confounding factors while comparing 
a category variable between the two groups in which the group variable will be treated as a 
predictor. 
8.5 Anticipated results 
We anticipate that our study will demonstrate non-inferiority in terms of early virological 
response, treatment failures and side effect profile in patients seen through telemedicine 
consultations compared to regular office visits. 
9. Conclusion 
Telemedicine consultation offers the potential to increase access to specialists in remote and 
underserved areas and may be an effective tool for identifying and treating patients with 
HCV who live in rural communities who may otherwise go untreated and progress to 
serious liver diseases, such as cirrhosis and cancer.  It offers a unique opportunity of real 
time interactions among the patient, the PCP, and the specialist.  Telemedicine can also be 
utilized to provide education to practitioners regarding HCV and provide clinical support to 
primary care providers in the complex management of HCV patients. Future outcomes 
research is needed to examine the safety and efficacy of telemedicine for the management of 
chronic diseases such as HCV. 
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Telemedicine" has been conceived to reflect this broad view and therefore has been split into two volumes,
each covering specific themes: Volume 1: Technologies, Enabling Factors and Scenarios; Volume 2:
Applications in Various Medical Disciplines and Geographical Regions. The current Volume 2 is structured into
the following thematic sections: Cardiovascular Applications; Applications for Diabetes, Pregnancy and
Prenatal Medicine; Further Selected Medical Applications; Regional Applications.
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